The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M.
Galimberti S, et al. Among authors: conte e.
J Chemother. 2007 Jun;19(3):315-21. doi: 10.1179/joc.2007.19.3.315.
J Chemother. 2007.
PMID: 17594928
Clinical Trial.